Published in Business

Norlase secures $11 million following ECHO approval

This is editorially independent content
2 min read

Norlase announced it has closed on an $11 million investment round of funding.

Give me a refresh on the company.

The Denmark-based company is developing a line of next-generation laser solutions to treat retina and glaucoma diseases, with a focus on ophthalmology, laser technology, medical device development, and customer care.

Notable products include the LEAF photocoagulator; the LION integrated green laser and laser indirect ophthalmoscope (LIO) along with ECHO, the industry’s first ultra-portable pattern scanning laser.

Didn’t we just hear about it?

Yup we did! The company announced earlier this month that the FDA granted 510(k) clearance for the ECHO Green Pattern Laser.  

See here for more details on that.

Let’s talk financing.

The company’s investment round (the biggest in its history, to date) was led by West Hill Capital, a London-based venture capital firm.

How will it be used?

According to Norlase, the company plans to accelerate production ramp-up of the ECHO, along with its other laser treatment solution products.

Go on …

With the ECHO being released in the United States and European Union, Norlase requires a significant increase in its production facility capacity in order to meet demand and continue investing in research and development.

Where can I demo the lasers?

You can go here to learn more or schedule a demo.